Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings
Nicole Briceno, Elizabeth Vera, Edina Komlódi-Pásztor, Zied Abdullaev, Anna Choi, Ewa Grajkowska, Tricia Kunst, Jason Levine, Matthew Lindsley, Kelly Fernandez, Jennifer Reyes, Lisa Boris, Eric Burton, Marissa Panzer, Lily Polskin, Marta Peñas-Prado, Tina Pillai, Brett Theeler, Jing Wu, Kathleen E. Wall, Antonios Papanicolau‐Sengos, Martha Quezado, James G. Smirniotopoulos, Kenneth Aldape, Terri S. Armstrong, Mark R. Gilbert
Abstract
Abstract Background Glioblastoma (GBM) is the most aggressive primary brain malignancy with <45% living a year beyond diagnosis. Previously published investigations of long-term survivors (LTS) provided clinical data but rarely incorporated a comprehensive clinical and molecular analysis. Herein, we identify clinical, imaging, molecular, and outcome features for 23 GBM-LTS patients and compare them with a matched cohort of short-term survivors (STS). Methods Molecularly confirmed Isocitrate Dehydrogenase (IDH) wildtype GBM patients living ≥3 years post-diagnosis (NLTS = 23) or <3 years (NSTS = 75) were identified from our Natural History study. Clinical and demographic characteristics were compared. Tumor tissue was analyzed with targeted next generation sequencing (NGS) (NLTS = 23; NSTS = 74) and methylation analysis (NLTS = 18; NSTS = 28). Pre-surgical MRI scans for a subset of LTS (N = 14) and STS control (N = 28) matched on sex, age, and extent of resection were analyzed. Results LTS tended to be younger. Diagnostic MRIs showed more LTS with T1 tumor hypointensity. LTS tumors were enriched for MGMTp methylation and tumor protein 53 (TP53) mutation. Three patients with classic GBM histology were reclassified based on NGS and methylation testing. Additionally, there were LTS with typical poor prognostic molecular markers. Conclusions Our findings emphasize that generalized predictions of prognosis are inaccurate for individual patients and underscore the need for complete clinical evaluation including molecular work-up to confirm the diagnosis. Continued accrual of patients to LTS registries that contain comprehensive clinical, imaging, tumor molecular data, and outcomes measures may pro\vide important insights about individual patient prognosis.